Pfizer explains their R&D Partnership Strategy. Uwe Schoenbeck.
Getting the right excellence of science in where it is needed and combining it with their own excellence of science is one of the key challenges that today's Pharma industry has to address.
Having defined ,over the last couple of years, their therapeutic areas of focus, Pfizer now aim to bring truly differentiated drugs forward to the patient. Partnering plays a large part in this and they have partnered across the board to achieve this. One of their initiatives , Centres for Therapeutic Innovation, allows them on highly promising projects to bring in academic investigators to work right next at the bench with their own scientists, hand in hand. Something which has not been frequently done in the past. During the World Pharma Licensing Summit in London last month Fiona Gardner talked to Uwe Schoenbeck, Chief Scientific Officer, External R&D Innovation, Senior Vice President, Worldwide R&D, about how R&D partnering works at Pfizer and the challenges and exciting areas of development.